Phacilitate Leaders World 

Phacilitate Leaders World & World Stem Cell Summit 2019 Agenda

Phacilitate Leaders World & World Stem Cell Summit 2019 Agenda

Loading
  1. Registration for Phacilitate Leaders World and World Stem Cell Summit opens
  1. Joint Pre-conference super plenary - The next 15 years for advanced therapies

    Regency Ballroom
  2. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  3. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  4. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  5. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  6. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  7. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  1. Drinks reception
  1. Registration for Phacilitate Leaders World and World Stem Cell Summit opens
  1. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

    Regency Ballroom
  2. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

    Regency Ballroom
  3. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

    Regency Ballroom
  4. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

    Regency Ballroom
  5. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

    Regency Ballroom
  6. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

    Regency Ballroom
  1. Word Stem Cell Summit Plenary

    THE ALPHA SESSION

    Ashe Auditorium
  2. Word Stem Cell Summit Plenary

    THE ALPHA CLINIC

  3. Word Stem Cell Summit Plenary

    THE ALPHA CLINIC

  1. Morning coffee break
  1. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

    Tuttle
  2. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

    Tuttle
  3. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

    Tuttle
  4. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

    Tuttle
  5. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

    Tuttle
  6. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

    Tuttle
  1. Manufacturing for commercialisation

    Lowering cost of goods: The evolution to making advanced therapies affordable and practical (Partnered with RMMS)

    Brickell
  2. Manufacturing for commercialisation

    Lowering cost of goods: The evolution to making advanced therapies affordable and practical (Partnered with RMMS)

    Brickell
  3. Manufacturing for commercialisation

    Lowering cost of goods: The evolution to making advanced therapies affordable and practical (Partnered with RMMS)

    Brickell
  4. Manufacturing for commercialisation

    Lowering cost of goods: The evolution to making advanced therapies affordable and practical (Partnered with RMMS)

    Brickell
  5. Manufacturing for commercialisation

    Lowering cost of goods: The evolution to making advanced therapies affordable and practical (Partnered with RMMS)

    Brickell
  6. Manufacturing for commercialisation

    Lowering cost of goods: The evolution to making advanced therapies affordable and practical (Partnered with RMMS)

    Brickell
  1. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

    Flagler
  2. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

    Flagler
  3. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

    Flagler
  4. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

    Flagler
  5. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

    Flagler
  6. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

    Flagler
  1. Standards workshops

    Mitigating clinical and business risk: standardising manufacturing practice in cell and gene therapies - Partnered with RMMS

    Orchid CD
  2. Standards workshops

    Mitigating clinical and business risk: standardising manufacturing practice in cell and gene therapies - Partnered with RMMS

    Orchid CD
  3. Standards workshops

    Mitigating clinical and business risk: standardising manufacturing practice in cell and gene therapies - Partnered with RMMS

    Orchid CD
  1. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

    Monroe
  2. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

    Monroe
  3. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

    Monroe
  4. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

    Monroe
  5. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

    Monroe
  6. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

    Monroe
  1. Discovery & translation

    The impact of converging technologies for stem cell research and translation

    Merrick I&II
  2. Discovery & translation

    The impact of converging technologies for stem cell research and translation

    Merrick I&II
  3. Discovery & translation

    The impact of converging technologies for stem cell research and translation

    Merrick I&II
  4. Discovery & translation

    The impact of converging technologies for stem cell research and translation

    Merrick I&II
  5. Discovery & translation

    The impact of converging technologies for stem cell research and translation

    Merrick I&II
  1. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

    Miami Lecture Hall
  2. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

    Miami Lecture Hall
  3. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

    Miami Lecture Hall
  4. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

    Miami Lecture Hall
  5. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

    Miami Lecture Hall
  6. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

    Miami Lecture Hall
  7. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

    Miami Lecture Hall
  1. Lunch break
  1. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

    Tuttle
  2. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

    Tuttle
  3. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

    Tuttle
  4. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

    Tuttle
  5. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

    Tuttle
  6. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

    Tuttle
  1. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

    Brickell
  2. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

    Brickell
  3. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

    Brickell
  4. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

    Brickell
  5. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

    Brickell
  6. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

    Brickell
  1. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

    Flagler
  2. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

    Flagler
  3. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

    Flagler
  4. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

    Flagler
  5. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

    Flagler
  6. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

    Flagler
  1. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

    Orchid CD
  2. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

    Orchid CD
  3. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

    Orchid CD
  4. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

    Orchid CD
  5. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

    Orchid CD
  1. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

    Monroe
  2. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

    Monroe
  3. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

    Monroe
  4. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

    Monroe
  5. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

    Monroe
  1. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

    Merrick I&II
  2. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

    Merrick I&II
  3. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

    Merrick I&II
  4. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

    Merrick I&II
  5. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

    Merrick I&II
  1. Regenerative medicine in the clinic

    Regenerative Medicine in Plastic Surgery

    Ashe Auditorium
  2. Regenerative medicine in the clinic

    Regenerative Medicine in Plastic Surgery

    Ashe Auditorium
  3. Regenerative medicine in the clinic

    Regenerative Medicine in Plastic Surgery

    Ashe Auditorium
  4. Regenerative medicine in the clinic

    Regenerative Medicine in Plastic Surgery

    Ashe Auditorium
  5. Regenerative medicine in the clinic

    Regenerative Medicine in Plastic Surgery

    Ashe Auditorium
  6. Regenerative medicine in the clinic

    Regenerative Medicine in Plastic Surgery

    Ashe Auditorium
  1. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

    Miami Lecture Hall
  2. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

    Miami Lecture Hall
  3. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

    Miami Lecture Hall
  4. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

    Miami Lecture Hall
  5. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

    Miami Lecture Hall
  1. Afternoon coffee break
  1. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

    Tuttle
  2. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

    Tuttle
  3. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

    Tuttle
  4. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

    Tuttle
  5. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

    Tuttle
  1. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

    Brickell
  2. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

    Brickell
  3. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

    Brickell
  4. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

    Brickell
  5. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

    Brickell
  6. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

    Brickell
  1. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

    Flagler
  2. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

    Flagler
  3. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

    Flagler
  4. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

    Flagler
  5. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

    Flagler
  1. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

    Orchid CD
  2. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

    Orchid CD
  3. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

    Orchid CD
  4. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

    Orchid CD
  5. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

    Orchid CD
  1. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

    Merrick I&II
  2. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

    Merrick I&II
  3. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

    Merrick I&II
  4. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

    Merrick I&II
  5. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

    Merrick I&II
  1. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

    Ashe Auditorium
  2. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

    Ashe Auditorium
  3. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

    Ashe Auditorium
  4. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

    Ashe Auditorium
  5. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

    Ashe Auditorium
  1. Perspectives on the regenerative medicine ecosystem

    Cutting edge issues in the intersection of ethics, law, science and journalism

    Miami Lecture Hall
  2. Perspectives on the regenerative medicine ecosystem

    Cutting edge issues in the intersection of ethics, law, science and journalism

    Miami Lecture Hall
  1. Twilight roundtables

    Promenade Upper
    High Quality Raw Materials from Clinical to Commercial Phase
  2. Twilight roundtables

    Promenade Upper
    In house or outsourced manufacturing – what are the key driving factors for this decision?
  3. Twilight roundtables

    Promenade Upper
    Challenges in allogeneic stem cell therapy: delivery, engraftment, efficacy and durability
  4. Twilight roundtables

    Promenade Upper
    Cost drivers in Mesenchymal Stem/Stromal Cell manufacturing, and technology strategies to address them
  5. Twilight roundtables

    Promenade Upper
    Addressing pain points in scale-up viral vector production – commercial and technical perspectives
  6. Twilight roundtables

    Promenade Upper
    Are serum free conditions the answer to standardisation, quality control and lowering COG's for starting materials?
  1. Registration for Phacilitate Leaders World and World Stem Cell Summit
  1. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

    Regency Ballroom
  2. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

    Regency Ballroom
  3. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

  4. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

    Regency Ballroom
  5. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

    Regency Ballroom
  6. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

    Regency Ballroom
  1. Morning coffee break
  1. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

    Tuttle
  2. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

    Tuttle
  3. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

    Tuttle
  4. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

    Tuttle
  5. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

    Tuttle
  6. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

    Tuttle
  7. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

    Tuttle
  1. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

    Brickell
  2. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

    Brickell
  3. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

    Brickell
  4. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

    Brickell
  5. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

    Brickell
  6. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

    Brickell
  1. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

    Flagler
  2. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

    Flagler
  3. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

    Flagler
  4. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

    Flagler
  5. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

    Flagler
  1. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

    Orchid CD
  2. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

    Orchid CD
  3. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

    Orchid CD
  4. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

    Orchid CD
  5. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

    Orchid CD
  1. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

    Miami Lecture Hall
  2. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

    Miami Lecture Hall
  3. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

    Miami Lecture Hall
  4. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

    Miami Lecture Hall
  5. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

    Miami Lecture Hall
  1. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

    Merrick I&II
  2. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

    Merrick I&II
  3. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

    Merrick I&II
  4. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

    Merrick I&II
  5. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

    Merrick I&II
  1. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

    Ashe Auditorium
  2. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

    Ashe Auditorium
  3. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

    Ashe Auditorium
  4. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

    Ashe Auditorium
  5. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

    Ashe Auditorium
  1. Lunch break
  1. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

    Tuttle
  2. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

    Tuttle
  3. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

    Tuttle
  4. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

    Tuttle
  5. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

    Tuttle
  6. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

    Tuttle
  1. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

    Brickell
  2. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

    Brickell
  3. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

    Brickell
  4. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

    Brickell
  5. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

    Brickell
  6. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

    Brickell
  1. Healthcare

    The next phase of data management, transfer and analysis

    Flagler
  2. Healthcare

    The next phase of data management, transfer and analysis

    Flagler
  3. Healthcare

    The next phase of data management, transfer and analysis

    Flagler
  4. Healthcare

    The next phase of data management, transfer and analysis

    Flagler
  5. Healthcare

    The next phase of data management, transfer and analysis

    Flagler
  6. Healthcare

    The next phase of data management, transfer and analysis

    Flagler
  1. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

    Orchid CD
  2. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

    Orchid CD
  3. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

    Orchid CD
  4. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

    Orchid CD
  1. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

    Miami Lecture Hall
  2. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

    Miami Lecture Hall
  3. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

    Miami Lecture Hall
  4. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space - Part 2

    Miami Lecture Hall
  5. Cord blood & Perinatal Stem Cells
    Miami Lecture Hall
  6. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

    Miami Lecture Hall
  1. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

    Merrick I&II
  2. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

    Merrick I&II
  3. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

    Merrick I&II
  4. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

    Merrick I&II
  5. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

    Merrick I&II
  1. Afternoon coffee break
  1. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

    Brickell
  2. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

    Brickell
  3. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

    Brickell
  4. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

    Brickell
  5. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

    Brickell
  6. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

    Brickell
  1. Healthcare

    Standardising Clinical Centres of Excellence

    Flagler
  2. Healthcare

    Standardising Clinical Centres of Excellence

    Flagler
  3. Healthcare

    Standardising Clinical Centres of Excellence

    Flagler
  4. Healthcare

    Standardising Clinical Centres of Excellence

    Flagler
  5. Healthcare

    Standardising Clinical Centres of Excellence

    Flagler
  6. Healthcare

    Standardising Clinical Centres of Excellence

    Flagler
  1. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

    Orchid CD
  2. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

    Orchid CD
  3. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

    Orchid CD
  4. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

    Orchid CD
  5. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

    Orchid CD